These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19835382)
1. Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics. Poon SF; St Jean DJ; Harrington PE; Henley C; Davis J; Morony S; Lott FD; Reagan JD; Lu JY; Yang Y; Fotsch C J Med Chem; 2009 Nov; 52(21):6535-8. PubMed ID: 19835382 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Nagano N Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839 [TBL] [Abstract][Full Text] [Related]
5. [Apoptosis: a possible mechanism of suppressing parathyroid hyperplasia by calcimimetics]. Mizobuchi M; Saji F; Shiizaki K; Sato T; Shibata M; Negi S; Akizawa T; Hatamura I; Ogata H; Kinugasa E Clin Calcium; 2005 Sep; 15 Suppl 1():56-8; discussion 58-9. PubMed ID: 16272631 [TBL] [Abstract][Full Text] [Related]
6. Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism. Wehn PM; Harrington PE; Carlson TJ; Davis J; Deprez P; Fotsch CH; Grillo MP; Lu JY; Morony S; Pattabiraman K; Poon SF; Reagan JD; St Jean DJ; Temal T; Wang M; Yang Y; Henley C; Lively SE Bioorg Med Chem Lett; 2013 Dec; 23(24):6625-8. PubMed ID: 24215889 [TBL] [Abstract][Full Text] [Related]
7. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262 [TBL] [Abstract][Full Text] [Related]
9. The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core. Harrington PE; St Jean DJ; Clarine J; Coulter TS; Croghan M; Davenport A; Davis J; Ghiron C; Hutchinson J; Kelly MG; Lott F; Lu JY; Martin D; Morony S; Poon SF; Portero-Larragueta E; Reagan JD; Regal KA; Tasker A; Wang M; Yang Y; Yao G; Zeng Q; Henley C; Fotsch C Bioorg Med Chem Lett; 2010 Sep; 20(18):5544-7. PubMed ID: 20708930 [TBL] [Abstract][Full Text] [Related]
10. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure]. Negri AL; Slatopolsky EA Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088 [TBL] [Abstract][Full Text] [Related]
12. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042 [TBL] [Abstract][Full Text] [Related]
13. Prevention of uremic bone disease using calcimimetic compounds. Olgaard K; Lewin E Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775 [TBL] [Abstract][Full Text] [Related]
14. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574 [TBL] [Abstract][Full Text] [Related]
15. Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat. Maillard MP; Tedjani A; Perregaux C; Burnier M J Hypertens; 2009 Oct; 27(10):1980-7. PubMed ID: 19593209 [TBL] [Abstract][Full Text] [Related]
16. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro. Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847 [TBL] [Abstract][Full Text] [Related]
17. Calcimimetic agents: review and perspectives. Ureña P; Frazão JM Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives. Yoshida M; Mori A; Kotani E; Oka M; Makino H; Fujita H; Ban J; Ikeda Y; Kawamoto T; Goto M; Kimura H; Baba A; Yasuma T J Med Chem; 2011 Mar; 54(5):1430-40. PubMed ID: 21306167 [TBL] [Abstract][Full Text] [Related]
19. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Wada M; Nagano N; Furuya Y; Chin J; Nemeth EF; Fox J Kidney Int; 2000 Jan; 57(1):50-8. PubMed ID: 10620187 [TBL] [Abstract][Full Text] [Related]